Figure 1. NRG-GI004/SWOG-S1610

NOTE: Arm 2 had been closed to accrual inAmendment #5. With Amendment #6, Arm 2 is restored to accrual and Arm 1 is closed.



Study Regimen:

* **Arm 1:** ***mFOLFOX6/bevacizumab until disease progression. Discontinue oxaliplatin after Cycle 10 (1 cycle = 2 weeks)***

- Oxaliplatin 85 mg/m^2 IV + leucovorin 400 mg/m^2 IV + bevacizumab 5 mg/kg IV+ 5-FU 400 mg/m^2 IV bolus on Day 1 followed by 5-FU 2400 mg/m^2 IV over 46 hours (Days 1 and 2)
- In the event of unacceptable toxicity without disease progression, including grade ≥ 3 neuropathy, individual components of mFOLFOX6/bevacizumab may be discontinued at the physician's discretion. All other components of mFOLFOX6/bevacizumab may be continued at their current dose and schedule.

** **Arm 2:** ***Atezolizumab monotherapy until disease progression and/or unacceptable toxicity or up to and including a maximum of 48 cycles (1 cycle = 2 weeks)***

- Atezolizumab 840 mg IV on Day 1 of every cycle

*****Arm 3:** ***mFOLFOX6/bevacizumab/atezolizumab until disease progression. Discontinue oxaliplatin after Cycle 10; discontinue atezolizumab after Cycle 48 (1 cycle = 2 weeks)***

- mFOLFOX6/bevacizumab same as Arm 1 + atezolizumab 840 mg IV on Day 1 of every cycle
- In the event of unacceptable toxicity without disease progression, including grade ≥ 3 neuropathy, individual components of mFOLFOX6/bevacizumab/atezolizumab may be discontinued at the physician's discretion. All other components of mFOLFOX6/bevacizumab/ atezolizumab may be continued at their current dose and schedule.

Note: *At disease progression, study therapy will be discontinued. Further treatment is at the investigator's discretion; however, patients will continue to be followed for survival.*